These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7771101)

  • 1. [Hormone substitution with premarin plus. Results of an Austrian multicenter treatment study].
    Kazar T; Neumann K; Windsteig E
    Wien Med Wochenschr; 1995; 145(1):18-21. PubMed ID: 7771101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium].
    Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F
    J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
    Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
    Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Continuous postmenopausal estrogen-progesterone therapy].
    Affinito P; Tommaselli GA; Morgera R; Rinaldi M; Di Mauro P; Nappi C
    Minerva Ginecol; 1993 Mar; 45(3):77-85. PubMed ID: 8392669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related cognitive decline in the menopause: effects of hormone replacement therapy on cognitive event-related potentials.
    Anderer P; Saletu B; Gruber D; Linzmayer L; Semlitsch HV; Saletu-Zyhlarz G; Brandstätter N; Metka M; Huber J
    Maturitas; 2005 Jul; 51(3):254-69. PubMed ID: 15978969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Italian multicenter study for the verification of the efficacy and tolerability of short-term substitution hormone therapy using conjugated estrogens and progestagens administered orally in the postmenopausal a period].
    De Aloysio D; Mauloni M; Altieri P; Cappi GP; Monterubbianesi M; Bottiglioni F
    Minerva Ginecol; 1992 Dec; 44(12):629-39. PubMed ID: 1491771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control.
    Aguilar-Salinas CA; Arita Melzer O; Sauque Reyna L; Lopez A; Velasco Perez ML; Guillen LE; Gomez Perez FJ; Rull Rodrigo JA
    Isr Med Assoc J; 2001 Feb; 3(2):137-43. PubMed ID: 11344825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
    Pomerantz M; Manola J; Taplin ME; Bubley G; Inman M; Lowell J; Beard C; Kantoff PW; Oh WK
    J Urol; 2007 Jun; 177(6):2146-50. PubMed ID: 17509304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the dose of hormone replacement therapy.
    Rice VM
    Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
    Obstet Gynecol; 2008 Nov; 112(5):1189-92. PubMed ID: 18978127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.
    Nevitt MC; Felson DT; Williams EN; Grady D
    Arthritis Rheum; 2001 Apr; 44(4):811-8. PubMed ID: 11315920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adequate reduction degree of pituitary gonadotropin levels in the clinical management of short-term hormone replacement therapy of women with menopausal symptoms.
    Ushiroyama T; Sakuma K; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):281-94. PubMed ID: 18084886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.
    Comerci JT; Fields AL; Runowicz CD; Goldberg GL
    Gynecol Oncol; 1997 Mar; 64(3):425-30. PubMed ID: 9062144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new peroral estrogen/progestin combination for postmenopausal hormonal substitution: an open multicentric field study.
    Haenggi W; Birkhaeuser MH
    Maturitas; 1993 Mar; 16(2):111-22. PubMed ID: 8387150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Estrogen and progestin treatment in postmenopause. Effects on the endometrium].
    Grio R; Curti A; Gobbi F; Piacentino R
    Minerva Ginecol; 1998 Dec; 50(12):553-6. PubMed ID: 10069171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin.
    Miller VT; Muesing RA; LaRosa JC; Stoy DB; Fowler SE; Stillman RJ
    Obstet Gynecol; 1994 Feb; 83(2):173-9. PubMed ID: 8290177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
    Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.